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Abstract
Introduction We compared the effects of mechanical
ventilation with a lower tidal volume (VT) strategy versus those of
greater VT in patients with or without acute lung injury (ALI)/
acute respiratory distress syndrome (ARDS) on the use of
opioids and sedatives.
Methods This is a secondary analysis of a previously conducted
before/after intervention study, which consisting of feedback
and education on lung protective mechanical ventilation using
lower VT. We evaluated the effects of this intervention on
medication prescriptions from days 0 to 28 after admission to
our multidisciplinary intensive care unit.
Results Medication prescriptions in 23 patients before and 38
patients after intervention were studied. Of these patients, 10
(44%) and 15 (40%) suffered from ALI/ARDS. The VT of ALI/
ARDS patients declined from 9.7 ml/kg predicted body weight
(PBW) before to 7.8 ml/kg PBW after the intervention (P =
0.007). For patients who did not have ALI/ARDS there was a
trend toward a decline from 10.2 ml/kg PBW to 8.6 ml/kg PBW
(P = 0.073). Arterial carbon dioxide tension was significantly
greater after the intervention in ALI/ARDS patients. Neither the
proportion of patients receiving opioids or sedatives, or
prescriptions at individual time points differed between pre-
intervention and post-intervention. Also, there were no
statistically significant differences in doses of sedatives and
opioids. Findings were no different between non-ALI/ARDS
patients and ALI/ARDS patients.
Conclusion Concerns regarding sedation requirements with
use of lower VT are unfounded and should not preclude its use
in patients with ALI/ARDS.
Introduction
One recent and substantive advance in the field of intensive
care medicine has been the clear demonstration by the ARDS
Network investigators [1] of the benefit conferred by lung pro-
tective (LP) mechanical ventilation (MV) among patients with
acute lung injury (ALI)/acute respiratory distress syndrome
(ARDS). Specifically, LP MV with lower tidal volume (VT; 6 ml/
kg predicted body weight [PBW]), as opposed to conven-
tional MV using larger VT (12 ml/kg PBW), was found to result
in significant reductions in mortality and morbidity in these
patients. A recent study conducted by the same investigators
[2] confirmed that use of use of lower VT is associated with a
low mortality rate. Despite the impressive results of the ARDS
Network trial, many intensive care units (ICUs) have been slow
ALI = acute lung injury; ARDS = acute respiratory distress syndrome; FiO2 = fractional inspired oxygen; ICU = intensive care unit; LP = lung protec-
tive; MV = mechanical ventilation; PaO2 = arterial oxygen tension; PBW = predicted body weight; Pmax = maximum airway pressure; RR = respiratory 
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to adopt LP MV [3]. Among the reasons for not adopting LP
MV was the concern that its use would necessitate or increase
prescription of sedatives and opioids because of patient intol-
erance of lower VT and increased respiratory rate (RR). Two
secondary analysis of the ARDS Network trial, however, have
clearly shown that lower VT ventilation does not increase seda-
tion requirements in the first few days after initiation of MV in
patients with ALI/ARDS [4,5].
We recently proposed that LP MV be employed in all intubated
and mechanically ventilated patients, irrespective of the pres-
ence or absence of ALI/ARDS [6]. There are several reasons
not to separate patients with from those without ALI/ARDS.
First, diagnosing ALI/ARDS is at times challenging [3]. Indeed,
although the consensus criteria appear relatively simple to
apply [7], use of higher levels of positive end-expiratory pres-
sure can improve both the arterial oxygen tension (PaO2)/frac-
tional inspired oxygen (FiO2) ratio and abnormalities on chest
radiographs to the extent that the patients no longer have ALI/
ARDS (by definition) [8,9]. Second, patients may not yet fulfill
consensus criteria at the initiation of MV but they may develop
ALI/ARDS during the course of their disease. Third, critically ill
patients are at constant risk for lung injury from other causes
(for example, ventilator-associated pneumonia and transfu-
sion-related ALI). A multiple hit theory can be suggested, in
which repeated challenges lead to the clinical picture of ALI/
ARDS. Unfortunately, however, no studies have yet investi-
gated sedation requirements in patients who are not suffering
from ALI/ARDS.
The present analysis was performed for the following reasons.
First, we wondered whether the adoption of LP MV would
affect sedation requirements in our ICU, where a strict seda-
tion protocol is applied that is aimed at achieving the lowest
possible level of sedation [10,11]. Second, because we favor
the use of LP MV using lower VT in all patients, irrespective of
the presence or absence of ALI/ARDS, we were interested in
whether sedation requirements change with the use of lower
VT in patients who are not suffering from ALI/ARDS. Finally,
because the ARDS Network protocol prescribed the use of
lower VT throughout ventilation (also with spontaneous MV at
later time points), we wished to determine the impact of lower
VT on sedation requirements in patients for a longer period (not
only during the first few days of MV).
Materials and methods
This is a secondary analysis of consecutive patients included
in an interventional multicentre study [12]. In this study we
determined the effect of feedback and education on use of
lower VT in intubated and mechanically ventilated patients. The
study included patients managed using a conventional VT
strategy (before feedback and education; conducted in June
2003) and patients ventilated using a lower VT strategy (after
this intervention; performed in January 2004) in our ICU. Only
patients who were intubated and mechanically ventilated for
longer than 24 hours were included. The study protocol was
approved by the local ethics committee; informed consent was
not deemed necessary because of the retrospective observa-
tional nature of this study and because the study did not
require modification to diagnostic or therapeutic strategies.
Intervention
The intervention has been described previously [12]. It con-
sisted of four components. The first component was a concise
presentation to all ICU physicians on results from several ani-
mal studies [13,14] and clinical studies of LP MV using lower
VT in ALI/ARDS patients [1,15-20]. The second component a
reminder about what was stated in our local MV guideline on
size of VT (VT should be 6 to 8 ml/kg PBW) and a reminder that
we all agreed to use lower VT when this guideline was intro-
duced. The third component was a presentation of data on the
actual size of VT before this intervention ('feedback'), for which
two of the investigators (EKW and MJS) recorded all ventilator
settings in all patients over a period of 2 weeks. The fourth and
final component was a discussion of potential reasons for not
using lower VT  (including the importance of using PBW
instead of actual bodyweight to set VT) and potential concerns
that lower VT will increase the need for sedation to maintain
ventilator synchrony and comfort ('education'). The same strat-
egy was employed for the ICU nurse team.
This intervention was repeated three times. Finally, the patient
data management system (PDMS; Metavision, iMDsoft, Sas-
senheim, The Netherlands) was equipped with a special tool
that automatically calculated the ideal VT from patient's height,
after which the targets were automatically generated in the
'respiratory tab' (for all patients it was easy to check whether
VT was between 6 and 8 ml/kg PBW).
Mechanical ventilation guideline
Our local MV guideline has previously been described [12]. In
short, before the intervention the guideline stated that pres-
sure controlled or pressure support MV should be used in all
patients. The guideline advised use of VT between 6 and 8 ml/
kg PBW. After the intervention, the guideline explicitly advised
that LP MV be used with lower VT (6 ml/kg PBW). Of note,
although it was mentioned in the guideline that a RR above 20
breaths/min was considered uncomfortable for patients
before the intervention, after the intervention no statements
were given regarding RR.
In our ICU, the pressure level with pressure controlled or pres-
sure support was adjusted to achieve the target VT. Because
it was unit policy that both nurses and physicians were able to
adjust ventilatory settings on a hourly basis, 24 hours per day,
VT  settings were subject to frequent adjustment and
refinement.Available online http://ccforum.com/content/11/4/R77
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Sedation guideline
In our institution, standard intravenous sedation consists of the
combined infusion of morphine and midazolam with 50 ml
syringes pre-filled with 50 mg midazolam plus 50 mg morphine
in sterile saline or glucose. Propofol can be used in addition,
when high dosages of morphine and midazolam are needed,
or solely, when frequent neurological evaluation is warranted.
Morphine can also be used separately to control pain when
there is no further need for sedation. The goals of sedation are
to reduce agitation, stress and fear; to reduce oxygen con-
sumption (heart rate, blood pressure and minute volume are
measured continuously); and to reduce physical resistance to
and fear of medical examination and daily care.
According to the guideline (Figure 1), nurses and physicians
determine the level of sedation required each day. Every 2
hours, the adequacy of sedation in each patient is carefully
evaluated using a Sedation Intensive Care (SEDIC) score, and
the infusion of sedatives is adjusted accordingly [10]. The
SEDIC score consists of five levels of stimuli (from normal
speech to nail bed pressure) and five levels of responsiveness
(from normal contact to no contact). Sedation levels are
defined by the sum of stimulus and response. When a SEDIC
score above 8 is reached, infusion of sedation is reduced. In
addition, patients weaned from midazolam receive low-dose
oral benzodiazepines (lorazepam and temazepam). Haloperi-
dol is given only to agitated or delirious patients.
Clinical data collection
The following baseline data were extracted following initiation
of MV: sex, body weight, height, admission diagnosis, and
Acute Physiology and Chronic Health Evaluation (APACHE) II
score. The diagnosis of ALI/ARDS was made by two investi-
gators (EKW and MJS) using the consensus criteria for ALI/
ARDS [7]. Ventilator settings were recorded at four different
time points each day (08:00; 12:00, 18:00 and 24:00 hours)
for a maximum period of 29 days. MV data (VT, maximum air-
way pressure [Pmax], positive en-expiratory pressure, RR, MV
Figure 1
Diagram of the sedation protocol and SEDIC score Diagram of the sedation protocol and SEDIC score. ICU, intensive care unit; IV, intravenous; MV, mechanical ventilation; SEDIC, Sedation Intensive 
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mode, FiO2, PaO2 and PaCO2) and sedation data (dose and
timing of sedatives and opioids) were extracted from the
PDMS, also for a maximum period of 29 days. Medication
doses were recorded beginning on the day of MV initiation and
ending at patients death, termination of MV, or day 29 of MV.
Patients who were re-intubated within 24 hours remained in
the analysis. Daily doses of morphine, midazolam and propofol
were calculated. Doses included both intravenous boluses
administered on an as-needed basis and continuous intrave-
nous infusions. Sedation given for intubation or tracheotomy
was not included in the calculations.
Statistical analysis
Data are presented for the whole study period. Data are pre-
sented as mean ± standard deviation for normally distributed
data, or as median (interquartile range) for data that are not
normally distributed. Differences between two groups were
assessed using a Mann-Whitney U-test or Student's t-test for
continuous variables; differences between four groups were
assessed using Kruskal-Wallis test or one-way analysis of var-
iance. χ2 test was used for categorical variables. Linear mixed
model analysis was used to study changes over time in
patients. This type of analysis takes into account the associa-
tion between values for individual patients measured at each
time point. This implies a maximum of 29 time points per
patient. The fixed effects were day of MV (0 to 28), group
(before or after feedback and education, and having ALI/
ARDS or not) and the interaction between group and day of
MV. Data obtained with linear mixed model analysis are pre-
sented as mean (95% confidence interval). Statistical calcula-
Table 1
Demographic variables
Before intervention (n = 23) After intervention (n = 38) P value
Non-ALI/ARDS (n = 13) ALI/ARDS (n = 10) Non-ALI/ARDS (n = 23) ALI/ARDS (n = 15)
Male (n [%]) 9 (69) 4 (40) 14 (61) 9 (60) 0.55
ABW (kg; median [IQR]) 70.0 (70.0 to 75.0) 75.0 (61.5 to 97.0) 76.0 (70.0 to 95.0) 70.0 (60.0 to 80.0) 0.25
PBW (kg; median [IQR]) 64.2 (52.4 to 70.6) 57.5 (52.6 to 70.1) 69.7 (59.7 to 75.1) 66.9 (57.9 to 75.1) 0.19
APACHE II (mean ± SD) 20.2 ± 7.5 22.8 ± 11.3 21.8 ± 7.1 19.9 ± 6.4 0.76
MVa (days; median [IQR]) 4.0 (3.0 to 11.5) 13.5 (6.5 to 26.0) 5.0 (2.0 to 8.0) 13.0 (5.0 to 22.0) 0.004
ICU death (n [%]) 2 (15) 7 (70) 3 (13) 4 (27) 0.005
PaO2/FiO2 ratiob (median [IQR]) 225 (194 to 264) 138 (120 to 157) 216 (173 to 268) 146 (100 to 187) < 0.001
Admission diagnosis (n (%])
Medical 2 (15.4) 1 (10) 2 (8.7) 7 (46.7)
Surgical 2 (15.4) 2 (20) 5 (21.7) 4 (26.7)
Neurology/neurosurgery 5 (38.5) 2 (20) 6 (26.1) 2 (13.3)
Cardiopulmonary surgery 2 (15.4) 3 (30) 3 (13.0) 2 (13.3)
Cardiology 2 (15.4) 2 (20) 6 (26.1) 0
P values were determined using χ2 test or one-way analysis of variance, comparing all four groups. aTotal number of mechanical ventilation (MV) 
days during the study period. bOn admission. ABW, actual body weight; ALI, acute lung injury; APACHE, Acute Physiology and Chronic Health 
Evaluation; ARDS, acute respiratory distress syndrome; PBW, predicted body weight.
Table 2
Respiratory variables for the whole period of 29 days
Before intervention (n = 23) After intervention (n = 38) P value
Non-ALI/ARDS (n = 13) ALI/ARDS (n = 10) Non-ALI/ARDS (n = 23) ALI/ARDS (n = 15)
VT (ml/kg PBW) 10.2 (9.3 to 11.1) 9.7 (8.9 to 10.5) 8.6 (7.8 to 9.5) 7.8 (7.2 to 8.5) <0.001
Pmax (cmH2O) 18.2 (13.0 to 23.4) 21.8 (18.1 to 25.5) 16.8 (11.4 to 22.2) 25.6 (22.8 to 28.5) 0.01
RR (breaths/min) 21.3 (18.4 to 24.3) 18.3 (16.1 to 20.6) 23.4 (20.5 to 26.4) 25.6 (23.7 to 27.6) <0.001
PaCO2 (kPa) 5.0 (4.3 to 5.7) 5.3 (4.8 to 5.8) 5.5 (4.9 to 6.2) 6.2 (5.8 to 6.6) 0.007
P values were determined using linear mixed model analysis, comparing all four groups. Values are expressed as mean (95% confidence interval). 
ALI, acute lung injury; ARDS, acute respiratory distress syndrome; PaCO2, partial pressure of arterial carbon dioxide; Pmax, maximum airway 
pressure; RR, respiratory rate; VT, tidal volume.Available online http://ccforum.com/content/11/4/R77
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tions were done using SPSS 12.0.1 (SPSS Inc., Chicago, IL,
USA). Differences with a P value < 0.05 were considered sta-
tistically significant.
Results
Patients
Baseline characteristics of 23 and 38 patients were collected
before and after the intervention, respectively (Table 1). ICU
mortality was 18% after the intervention as compared to 39%
before the intervention (P = 0.08). The number of ventilation
days was significantly greater in ALI/ARDS patients both
before and after the intervention, as compared with non-ALI/
ARDS patients. Also the PaO2/FiO2 ratio on admission was
significantly lower in ALI/ARDS patients in both groups.
Mechanical ventilation
VT was significantly lower after the intervention (Table 2). VT in
ALI/ARDS patients declined from 9.7 ml/kg PBW before to
7.8 ml/kg PBW after the intervention (P = 0.007); for non-ALI/
ARDS patients there was a trend toward a decline, from 10.2
ml/kg PBW to 8.6 ml/kg PBW (P = 0.073). Accordingly, RR
increased significantly in ALI/ARDS patients after the interven-
tion (P < 0.001). In addition, RR in non-ALI/ARDS patients
after the interventio n  w a s  h i g h e r  t h a n  t h a t  i n  A L I / A R D S
patients before the intervention (P  = 0.049). For non-ALI/
ARDS patients the RR did not increase after the intervention.
PaCO2 was significantly greater in ALI/ARDS patients after
the intervention than in non-ALI/ARDS patients (P = 0.017)
and ALI/ARDS patients (P = 0.034) before the intervention.
Pmax did not differ between the two study periods. However,
Pmax was significantly greater in ALI/ARDS patients than in
non-ALI/ARDS patients after the intervention (P = 0.031).
Prescription of sedatives and opioids
The mean doses of morphine, midazolam, or propofol for
mechanically ventilated patients on days 1, 7, 14, 21 and 28
are presented in Table 3. The percentages of mechanically
ventilated patients requiring morphine, midazolam, or propofol
for these time points are presented in Table 4. There were no
significant differences in terms of doses of morphine, mida-
zolam, or propofol before and after the intervention. Also, there
were no significant differences in the percentage of mechani-
cally ventilated patients needing morphine, midazolam, or pro-
pofol. Figure 2 shows the percentage of patients (either
mechanically ventilated or liberated from the ventilator) need-
ing morphine, midazolam, or propofol during the study period.
There were no differences for sedatives or opioids at any time
point.
Table 3
Dosing of opioids and sedative drugs at different time points
Before intervention n After intervention nP   value
Morphine
Day 1 0.54 ± 0.68 23 0.70 ± 0.85 38 0.55
Day 7 0.64 ± 0.99 11 0.49 ± 0.66 20 0.74
Day 14 0.53 ± 0.67 7 0.65 ± 0.72 8 0.90
Day 21 0.88 ± 0.78 3 0.06 ± 0.13 5 0.21
Day 28 0.25 ± 0.36 2 0.50 ± 0.81 3 0.67
Midazolam
Day 1 0.65 ± 1.0 23 0.84 ± 1.3 38 0.94
Day 7 0.82 ± 1.9 11 0.69 ± 1.8 20 0.80
Day 14 0.32 ± 0.58 7 1.7 ± 3.5 8 0.45
Day 21 0.40 ± 0.70 3 3.8 ± 8.6 5 0.42
Day 28 0.37 ± 0.52 2 6.0 ± 10.4 3 0.45
Propofol
Day 1 19.4 ± 35.3 23 13.5 ± 22.6 38 0.64
Day 7 3.0 ± 8.2 11 13.9 ± 29.8 20 0.49
Day 14 10.6 ± 27.8 7 21.8 ± 49.2 8 1.0
Day 21 24.6 ± 42.5 3 52.3 ± 97.6 5 0.60
Day 28 7.9 ± 11.2 2 32.0 ± 55.4 3 0.63
Data are presented in mg/kg per day as mean ± standard deviation. The P value was derived using the Student's t-test.Critical Care    Vol 11 No 4    Wolthuis et al.
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ALI/ARDS patients versus patients without acute lung 
injury
We used linear mixed model analysis to determine whether
there were changes over time before and after the intervention,
and whether the presence versus absence of ALI/ARDS
affected the use of morphine, midazolam, or propofol. When
patients were subdivided into ALI/ARDS patients and non-
ALI/ARDS patients, there was no difference in the mean dose
of sedative drugs for the different groups (Table 5). The per-
centage patients with ALI/ARDS needing morphine over the
entire study period was 70% before and 93% after interven-
tion (P = 0.12). The respective percentages were 80% and
87% for midazolam (P = 0.66), and 90% and 93% for propo-
fol (P = 0.76).
Discussion
Because preservation of neurological function is critical to the
accurate identification of clinical improvement or deterioration
in critically ill patients, sedation requires careful consideration
[21]. Prolonged sedation increases utilization of unnecessary
diagnostic studies [22], and it may lead to delayed extubation,
lengthening of the stay in the ICU and worsen clinical out-
comes [22,23]. High-dose, continuous sedation can also
decrease long-term quality of life [24]. Concerns that the need
for sedation will be increased by the use of LP MV with lower
VT are not supported by the findings of the present study; after
implementing this strategy in our ICU, patients did not require
higher levels of sedation or opioids as compared with patients
managed before implementation of the strategy.
There are several limitations to our study. First, it was an obser-
vational cohort study. Over recent years there has been grow-
ing awareness of the benefits of restrictive use of sedatives.
One may suggest that increased sedation requirements may
be masked by this improved awareness. We believe that this
time-dependent effect plays a minor role, because the two
periods of data collection are close together and our sedation
guideline did not change during the conduct of this study.
However, because we have a strict sedation guideline at our
ICU, it may be possible that we did not observe influences on
sedation requirements between the two groups, in particular
because both ICU physicians and nurses are very stringent in
applying the sedation guideline. Because of this, and perhaps
also because of other factors that are not easy to recognize
and that are unique to a single ICU, our results may not be
applicable to other ICUs. Third, the total number of patients
included in this study is quite small, especially when we subdi-
vide patients into those who have ALI/ARDS and those who
do not. It is therefore possible that type II errors (false-negative
results) occurred and that subgroup analysis is unreliable.
Table 4
Number of patients needing opioids and sedative drugs
Before intervention n After intervention nP   value
Morphine
Day 1 14 (61) 23 24 (63) 38 0.86
Day 7 4 (36) 11 11 (55) 20 032
Day 14 4 (57) 7 4 (50) 8 0.78
Day 21 2 (67) 3 1 (20) 5 0.19
Day 28 1 (50) 2 2 (67) 3 0.71
Midazolam
Day 1 11 (48) 23 16 (42) 38 0.61
Day 7 2 (18) 11 5 (25) 20 0.66
Day 14 2 (29) 7 3 (38) 8 0.71
Day 21 1 (33) 3 1 (20) 5 0.67
Day 28 1 (50) 2 2 (67) 3 0.71
Propofol
Day 1 10 (43) 23 14 (38) 38 0.66
Day 7 3 (27) 11 7 (35) 20 0.66
Day 14 2 (29) 7 3 (38) 8 0.88
Day 21 1 (33) 3 1 (20) 5 0.67
Day 28 1 (50) 2 1 (33) 3 0.71
Values are expressed as number (%). P values were determined using χ2 test.Available online http://ccforum.com/content/11/4/R77
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However, our findings are quite similar to those of a study con-
ducted by Cheng and coworkers [4]. In this secondary analy-
sis of the ARDS Network trial, no differences were found
between patients in the lower VT strategy and patients in the
conventional VT strategy in terms of the need for sedation or
neuromuscular blockade within 48 hours after admission.
Kahn and colleagues [5] reported a similar analysis and found
that there were no significant differences in the percentage of
study days during which patients received sedatives, opioids,
or neuromuscular relaxants (over a maximum period of 28
days). Our data extend the findings of these two studies by
showing that the same applies to patients who are not suffer-
ing from ALI/ARDS.
One important finding is that after intervention the mean VT
was 8.6 ml/kg PBW for non-ALI/ARDS patients and 7.8 ml/kg
PBW for ALI/ARDS patients (and not 6 ml/kg PBW, as was
the case in the ARDS Network trial [1]). Thus, the levels of VT
in our study, after the intervention, are better considered to be
'intermediate' volumes rather than 'low' volumes. In fact, it must
be recognized that the VTs are still high, and possibly too high
in both patient groups. However, VT settings in patients suffer-
ing from ALI/ARDS declined during the conduct of this study.
Nevertheless, the difference between VT before the interven-
tion and that after the intervention is small, which be why we
did not observe a difference between the two ventilation
groups in terms of need for sedation.
Conclusion
A decline in VT in ALI/ARDS patients at our center did not
increase sedation requirements. For non-ALI/ARDS patients
there was a trend toward a decline in VT from 10.2 ml/kg PBW
to 8.6 ml/kg PBW (P = 0.073). In these patients there was
also no increase in sedation needs. Concerns regarding the
potential adverse effects of LP MV should not preclude its use.
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Figure 2
Percentage of patients requiring sedative drugs Percentage of patients requiring sedative drugs. Shown are the per-
centages of patients needing (a) morphine, (b) midazolam, or (c) pro-
pofol from days 0 to 28 for patients mechanically ventilated before and 
after the intervention.
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